FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

The US Food and Drug Administration has granted approval to Pfizer's IBRANCE regimen for the frontline maintenance treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. This approval is based on data from the collaborative Phase 3 PATINA trial, which demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS) in patients treated with IBRANCE plus endocrine therapy compared to those receiving endocrine therapy alone. The trial showed that the addition of IBRANCE to endocrine therapy resulted in a 24% reduction in the risk of invasive disease recurrence or death, highlighting the potential of this regimen to improve outcomes for patients with HR+, HER2+ metastatic breast cancer. Notably, IBRANCE is the first and only CDK4/6 inhibitor approved for HR+ metastatic disease regardless of HER2 status, providing a new treatment option for a broader range of patients.